What's Next: Orforglipron (oral GLP-1) completing Phase 3 trials with submissions expected by year-end 2025 CEO Dave Ricks expects FDA approval by March 2026 International launches accelerating in China, Brazil, India, and Mexico The GLP-1 market is projected to exceed $100B+ by the early 2030s, and Lilly is positioned as the category leader
A dermatology study of telogen effluvium following weight loss found that shedding tended to begin roughly one to three months after the weight came off, and that it typically appeared once a person had lost around 15% of their body weight or was losing weight faster than about 3.5 kg a month
If appetite suppression and weight loss progress well at a given dose, there may be no need to increase further
10.3390/molecules200916970 7 DattaS
Whether or not their insurance plan covers weight loss drugs, employees can enroll in MediFit and gain access to medications like Wegovy and Ozempic at a significantly lower cost than whats typically available at retail pharmacies
